Member Info for SSBFANTX

@katstranglet I hear what ur saying, but I believe the safety issue will be more of a differentiator than “who has the cheapest battery”. Especially in the medical device, natl’ defense and consumer products marketplaces.

Medical Device: It's a very litigious world, (esp. in USA), and NO physician, surgeon or hospital/healthcare delivery system wants to explain to a jury, a medical board or their medical malpractice carrier as to why they opted for the ‘cheapest’ battery on the market, knowing there are much safer alternatives available.

Natl’ Defenses: This one is kinda obvious, but safety of their service members is the #1 considerations by those military decision-makers, who order their troops to deploy to the fight. So they will do all they can to give their brave warriors the best chance possible of coming home whole when their tour/deployment or war ends. And a safer battery pack that powers up all their critical equipment they use on the battle field everyday. Not to mention that most nations war departments (at least those in the west anyway) tend to “spend $$ (like drunk sailorss” ‘as the saying goes. They are extremely inefficient in the spending department, with enormous military budgets. I believe a war dept. will gladly spend a little more if nit gives their warriors a better chance of safely coming home. (Upright).

Consumer Products: Similar to medical device manufacturers, the fear of litigation from a consumer who may have been injured or killed using a ‘less safe’ but cheaper power source is a nightmare for manufacturers and a wet dream for a plaintiff’s quality control/product safety attorney! No thanks….

Anyway just my 2 cents. GLTA!

Well stated Cadellin. For several points per Cadellin, in the back of my mind I have always thought that when (IMO) ILIKA begins cranking up meaningful revenues, I can see them bundling up all their assets, (lease and royalty income, IP/Patent Catalog, pilot line equipment etc) and sell it ALL……but just TOO EARLY! (ex: Selling in 3yrs. for $4B when in another 8- 10 years it could be sold for $20B to $30b). To be clear, Im not insinuating that they will ever be worth $4B to $30B, just illustrating those #s as an example.

This is where you hope that over the next 2-3 yrs they will have forged and nurtured a few really solid investment banker relationships. As mostly brilliant scientists, it’s ok to ‘stay in your lane’ and keep working and developing in your field of expertise. (In fact I prefer you do just that). But have the wherewithal to hand over the mktg. and investment banking to those whom have expertise in those respective fields.

Anyway, new to the board but not new to Ilika. (Began a position in early 2020, and have aggressively added since) GLTA